SCHEMBL6263738

SCHEMBL6263738

Cc1cc(C(=O)N2CCN(c3cccc(C(N)=O)c3)CC2)n(-c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.56
LMNA P02545 4/20 0.51
MAPK1 P28482 3/20 0.51
USP2 O75604 2/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 2/20 0.50
PARP14 Q460N5 1/20 0.49
PARP10 Q53GL7 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 1/20 0.47
F2 P00734 1/20 0.47
F10 P00742 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418198 0.92 TSHR (0.60) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6261073 0.91 TSHR (0.56) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6262956 0.89 TSHR (0.58) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6261002 0.89 ALDH1A1 (0.53) TSHRLMNAMAPTALDH1A1KMT2A
SCHEMBL6416255 0.88 TSHR (0.65) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6261963 0.88 TSHR (0.53) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6415443 0.87 TSHR (0.59) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6415048 0.86 KMT2A (0.62) TSHRLMNAMAPK1USP2MAPT
SCHEMBL6261742 0.86 TSHR (0.58) TSHRLMNAMAPK1USP2MAPT
SCHEMBL29495713 0.86 LMNA (0.65) TSHRLMNAMAPK1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT TSHR 4236/4885LMNA 2233/4885MAPK1 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.